Back to Stocks

GH

Guardant Health, Inc.
7 filings tracked
healthcarebiotechnologyMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Guardant Health has reached a pivotal commercial inflection point, transitioning from a specialized liquid biopsy provider to a diversified leader in precision oncology.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the impressive top-line growth, Guardant Health continues to struggle with a widening operating abyss. The company's net loss increased to $112.1 million for the quarter, as the cost of acquiring new revenue remains unsustainably high.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every GH filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company in a high-stakes race between commercial scaling and financial sustainability. On one hand, the rapid adoption of the Shield test and the 36% growth in core oncology revenue prove that Guardant's technology is meeting a critical market need and can scale rapidly. The company's ability to maintain gross margins while increasing volume suggests that the underlying unit economics are improving as the business matures. However, the synthesis of the financial data shows a stark contrast between revenue growth and bottom-line performance. The widening net loss and the heavy reliance on a large cash pile to fund operations indicate that the company has yet to find a sustainable path to profitability. Investors are left weighing the potential of a multi-billion dollar screening market against the immediate risks of legal judgments and a heavy debt load. The ultimate trajectory of the stock will likely depend on whether the Shield platform can reach a critical mass of adoption that allows the company to pull back on its aggressive marketing spend without sacrificing growth.

Selected Quarter

Core Takeaway

Guardant is successfully scaling its product suite, but the cost of growth is eroding the bottom line and increasing financial risk.

Investor Lens

The trade-off between aggressive market share capture via high spending versus the need for a sustainable path to profitability.

Watch Next

The outcome of the May 2026 post-trial motions regarding the TwinStrand Biosciences verdict.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.15Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Net loss widened to $112.1 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 7

Maintained gross margins of ~65% despite a massive surge in screening test volumes.

margin expansion
50%
bullishMay 7

FDA granted Breakthrough Device designation for the Shield MCD test.

regulatory action
70%
neutralMay 7

Carries $1.5 billion in convertible senior notes with specific conversion triggers.

debt restructure
40%
bearishMay 7

Net loss widened to $112.1 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 7

Maintained gross margins of ~65% despite a massive surge in screening test volumes.

margin expansion
50%
bullishMay 7

FDA granted Breakthrough Device designation for the Shield MCD test.

regulatory action
70%
neutralMay 7

Carries $1.5 billion in convertible senior notes with specific conversion triggers.

debt restructure
40%
bearishMay 7

Net loss widened to $112.1 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 7

Maintained gross margins of ~65% despite a massive surge in screening test volumes.

margin expansion
50%
bullishMay 7

FDA granted Breakthrough Device designation for the Shield MCD test.

regulatory action
70%
neutralMay 7

Carries $1.5 billion in convertible senior notes with specific conversion triggers.

debt restructure
40%
bearishMay 7

Net loss widened to $112.1 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 7

Maintained gross margins of ~65% despite a massive surge in screening test volumes.

margin expansion
50%
bullishMay 7

FDA granted Breakthrough Device designation for the Shield MCD test.

regulatory action
70%
neutralMay 7

Carries $1.5 billion in convertible senior notes with specific conversion triggers.

debt restructure
40%
bearishMay 7

Net loss widened to $112.1 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 7

Maintained gross margins of ~65% despite a massive surge in screening test volumes.

margin expansion
50%
bullishMay 7

FDA granted Breakthrough Device designation for the Shield MCD test.

regulatory action
70%
neutralMay 7

Carries $1.5 billion in convertible senior notes with specific conversion triggers.

debt restructure
40%
bearishMay 7

Net loss widened to $112.1 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 7

Maintained gross margins of ~65% despite a massive surge in screening test volumes.

margin expansion
50%
bullishMay 7

FDA granted Breakthrough Device designation for the Shield MCD test.

regulatory action
70%
neutralMay 7

Carries $1.5 billion in convertible senior notes with specific conversion triggers.

debt restructure
40%
bearishMay 7

Net loss widened to $112.1 million as operating expenses outpaced revenue growth.

earnings miss
60%
bullishMay 7

Maintained gross margins of ~65% despite a massive surge in screening test volumes.

margin expansion
50%
bullishMay 7

FDA granted Breakthrough Device designation for the Shield MCD test.

regulatory action
70%
neutralMay 7

Carries $1.5 billion in convertible senior notes with specific conversion triggers.

debt restructure
40%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing reveals a company in a high-stakes race between commercial scaling and financial sustainability. On one hand, the rapid adoption of the Shield test and the 36% growth in core oncology revenue prove that Guardant's technology is meeting a critical market need and can scale rapidly. The company's ability to maintain gross margins while increasing volume suggests that the underlying unit economics are improving as the business matures. However, the synthesis of the financial data shows a stark contrast between revenue growth and bottom-line performance. The widening net loss and the heavy reliance on a large cash pile to fund operations indicate that the company has yet to find a sustainable path to profitability. Investors are left weighing the potential of a multi-billion dollar screening market against the immediate risks of legal judgments and a heavy debt load. The ultimate trajectory of the stock will likely depend on whether the Shield platform can reach a critical mass of adoption that allows the company to pull back on its aggressive marketing spend without sacrificing growth.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.